



Comparison Chart of COVID-19 and Influenza

	COVID-19	Influenza
Presentation	<ul style="list-style-type: none"> respiratory diseases with a wide range of illness from asymptomatic or mild through to severe disease and death 	<ul style="list-style-type: none"> respiratory disease with a wide range of illness from asymptomatic or mild through to severe disease and death
Mode of Transmission & Public Health Measures	<ul style="list-style-type: none"> spread through contact, droplets and fomites prevention includes hand hygiene and good respiratory etiquette 	<ul style="list-style-type: none"> spread through contact, droplets and fomites prevention includes hand hygiene and good respiratory etiquette
Median incubation period (time from infection to appearance of symptoms)	<ul style="list-style-type: none"> estimated at 5 days 	<ul style="list-style-type: none"> 1-4 days, mean of 2 days
Serial interval (time between successive cases)	<ul style="list-style-type: none"> estimated to be 5-6 days 	<ul style="list-style-type: none"> 3 days can spread faster than COVID-19
Major driver of transmission	<ul style="list-style-type: none"> adults (children are infected from adults) 	<ul style="list-style-type: none"> first 3-5 days of illness/pre-symptomatic transmission children (adults are infected from children)
Severity	<ul style="list-style-type: none"> 80% of infections are mild or asymptomatic 15% are severe infection requiring oxygen 5% are critical infections requiring ventilation. 	<ul style="list-style-type: none"> burden of influenza varies every year globally, an estimated 0.3% to 0.5% of influenza cases are severe
Most at risk	<ul style="list-style-type: none"> older age underlying conditions 	<ul style="list-style-type: none"> children pregnant women elderly underlying/chronic medical conditions immunosuppressed
Mortality	<ul style="list-style-type: none"> higher (3-4%) than for influenza (especially seasonal influenza) 	<ul style="list-style-type: none"> usually well below 0.1% determined by access to and quality of health care
Treatment	<ul style="list-style-type: none"> number of therapeutics currently in clinical trials in China more than 20 vaccines in development currently no licensed vaccines or therapeutics 	<ul style="list-style-type: none"> antivirals and vaccines available

References

Annals of Internal Medicine. (2020). The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Available at, <https://annals.org/aim/fullarticle/2762808/incubation-period-coronavirus-disease-2019-covid-19-from-publicly-reported>

National Advisory Committee on Immunization. (2020). Canadian Immunization Guide chapter on Influenza and statement on seasonal influenza vaccine for 2019-2020. Available at, https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/healthy-living/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2019-2020/NACI_Stmt_on_Seasonal_Influenza_Vaccine_2019-2020_v12.3_EN.pdf

Ontario Ministry of Health. (2020). Appendix A: Disease-specific chapters Influenza. Available at, http://www.health.gov.on.ca/en/pro/programs/publichealth/oph_standards/docs/influenza_chapter.pdf

Registered Nurses' Association of Ontario. (2020). Daily Updates available at, https://myrnao.ca/daily_situational_reports_from_ontarios_moh_eoc

